| 產(chǎn)品編號(hào) | BIO0404SM |
| 英文名稱(chēng) | Anti-human TNFRSF5 / CD40 (Selicrelumab Biosimilar) |
| 中文名稱(chēng) | |
| 抗體來(lái)源 | |
| 克隆類(lèi)型 | Monoclonal |
| 克 隆 號(hào) | |
| 交叉反應(yīng) | Human |
| 產(chǎn)品應(yīng)用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 146.2 kDa |
| 檢測(cè)分子量 | |
| 性 狀 | Lyophilized |
| 亞 型 | Human IgG2SA |
| 純化方法 | Protein A |
| 保存條件 | For long term storage, the produce should be stored at -20°C or lower. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 | |
| 產(chǎn)品圖片 |
Compared with the negative control group, selicrelumab had a significant increase in serum ALT content at a dose of 20 mpk, and a trend of increase in serum ALT at a dose of 1 mpk, but there was no statistica
Selicrelumab inhibited the tumor growth of MC38 on Humanized CD40 mice. The result showed significant anti-tumor effects.
Immobilized human CD40 His at 2 ug/mL can bind Anti-TNFRSF5 / CD40 Reference Antibody (selicrelumab), EC50=0.009782 ug/mL.
The purity of Anti-TNFRSF5 / CD40 Reference Antibody (selicrelumab) is more than 95%, determined by SEC-HPLC.
Anti-TNFRSF5 / CD40 Reference Antibody (selicrelumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
|
